James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Fitbit Inc (FIT) Stock Is Just a One-Hit Wonder

There's a reason Fitbit stock has fallen 70% over the course of the past year: FIT is fundamentally flawed.

Why Lowe’s Companies, Inc. (LOW), PDL BioPharma Inc (PDLI) and Mallinckrodt PLC (MNK) Are 3 of Today’s Worst Stocks

Wednesday was rough for owners of Lowe's (LOW), Mallinckrodt (MNK) and PDL BioPharma (PDLI), but for understandable reasons.

Target Corporation (TGT) Stock Jumps on Q3 Earnings Beat, But …

Target (TGT) managed to top Q3 expectations, but its struggles continue. This aggressive rally in Target stock could fizzle quickly.

Why Nokia Corp (ADR) (NOK), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Home Depot Inc (HD) Are 3 of Today’s Worst Stocks

Home Depot (HD), Teva Pharmaceutical (TEVA) and Nokia (NOK) were doomed from the start of Tuesday's trading.

Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions

VRX stock could fall another 93% if this analysis of Valeant Pharmaceuticals Intl Inc is on target... and it's not too far off target.